{"id":"W2531125083","doi":"10.1158/1078-0432.ccr-15-3069","title":"Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cégep de Saint-Laurent; Hôpital Notre-Dame","funders":"AbbVie","keywords":"Veliparib; Carboplatin; Medicine; Placebo; PARP inhibitor; Internal medicine; Lung cancer; Paclitaxel; Clinical endpoint; Oncology; Urology; Cancer; Surgery; Chemotherapy; Randomized controlled trial; Pathology; Cisplatin; Biology; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007043909,0.0002364149,0.001696225,0.0003489449,0.0001354947,0.00001637276,0.0001606965,0.0001142856,0.0001656701],"category_scores_gemma":[0.001374994,0.0001436898,0.000159158,0.0004403555,0.0006295765,0.0001181082,0.00007949414,0.0005132006,0.000001274754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000334928,"about_ca_system_score_gemma":0.0009206795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007016246,"about_ca_topic_score_gemma":0.001105124,"domain_scores_codex":[0.9956695,0.001020387,0.001343462,0.0006717451,0.0007497838,0.0005451593],"domain_scores_gemma":[0.9908212,0.007218292,0.0003853021,0.0004238299,0.0008947439,0.0002565706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.935886,0.004799736,0.0157147,0.0005207493,0.0004369714,0.00002008678,0.001392209,0.00005970989,0.003238204,0.00006014832,0.0006941343,0.03717732],"study_design_scores_gemma":[0.9808166,0.01076754,0.001148998,0.001194377,0.0002951984,0.000001620071,0.000723335,0.002263972,0.00203665,0.0003531731,0.000207918,0.0001906424],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803885,0.003329026,0.001057083,0.001963511,0.0001834205,0.01270208,0.0000906733,0.00001818612,0.0002675396],"genre_scores_gemma":[0.983402,0.002485265,0.0005026094,0.0001284236,0.0001590585,0.01189841,0.000006015197,0.00005100359,0.001367173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04493055,"threshold_uncertainty_score":0.58595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1396071167747304,"score_gpt":0.5230751276709501,"score_spread":0.3834680108962196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}